Thus, a recent study has shown that the 3-year overall survival rates for BRAFV600E-mutated and BRAF wild-type metastatic colorectal cancer patients were 54% and 82.9%, respectively [2]. The gene discussed is BRAF; the disease is metastatic colorectal cancer.